Buy Datroway in India — Price & Availability

Datroway (datopotamab deruxtecan-dlnk) is a TROP2-directed antibody-drug conjugate. It links a monoclonal antibody that targets the TROP2 protein on cancer cells to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a cleavable linker, delivering the cytotoxic drug more directly to the tumour.

It is approved for adults with:

• HR-positive, HER2-negative breast cancer — unresectable or metastatic hormone receptor-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer, after prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
• Triple-negative breast cancer (TNBC) — unresectable or metastatic TNBC in patients who are not candidates for PD-1/PD-L1 inhibitor therapy (a first-line option approved in 2026).
• EGFR-mutated non-small cell lung cancer (NSCLC) — locally advanced or metastatic EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy (granted under accelerated approval based on response rate and duration of response).

The relevant receptor or mutation status must be confirmed before treatment. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended dosage:
The recommended dose of Datroway is 6 mg/kg given as an intravenous infusion once every 3 weeks (a 21-day cycle), continued until disease progression or unacceptable toxicity. The first infusion is given more slowly with observation; later infusions may be given over a shorter time if well tolerated. Premedication (including anti-nausea medicines and, per the label, medicines to reduce eye and mouth side effects) is given, along with recommended eye care and mouth care. Datroway is given only as an IV infusion. The treating oncologist always determines dosing and any modifications.

Datroway’s prescribing information includes the following key warnings and precautions:

• Interstitial lung disease (ILD) / pneumonitis: can be severe, life-threatening, or fatal; report new or worsening cough, shortness of breath, or fever promptly, as treatment may need to be interrupted or stopped.
• Ocular (eye) toxicity: including dry eye, keratitis, and other corneal effects; eye examinations and prophylactic eye care are recommended, and contact-lens use may be restricted.
• Stomatitis (mouth sores): common; mouth care and, per the label, steroid mouthwash are used to reduce severity.
• Embryo-fetal toxicity: Datroway can harm an unborn baby; effective contraception is advised, and breastfeeding is not recommended during and for a period after treatment.

Common side effects:
Common side effects include nausea, fatigue, hair loss (alopecia), mouth sores (stomatitis), constipation, vomiting, dry eye and other eye changes, decreased appetite, and changes in certain blood tests. This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Datroway through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
  Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Cold-chain import & delivery — Datroway is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.

Documents required to import Datroway:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports (including receptor status and, for lung cancer, EGFR mutation results)
• Government-issued patient ID proof
• An import permit, where applicable

Indian Pharma Network sources Datroway from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Datroway vials require cold-chain handling: stored refrigerated at 2 °C–8 °C in the original carton, protected from light, and not frozen or shaken. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Is Datroway available in India?

Datroway (datopotamab deruxtecan-dlnk injections) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, Datroway is not commercially marketed in India.

However, patients in India can legally access Datroway through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Datroway in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  Datroway price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
• Ensuring full transparency throughout the process

Datroway can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

How does Datroway Import in India work?

Datroway Import in India can be done through the Named Patient Program (NPP). This means the medicine can be imported on behalf of the patient with a valid doctor’s prescription. Indian Pharma Network (IPN) helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

How can I buy Datroway in India?

Datroway is not commercially marketed in India, but it can be legally accessed through the Named Patient Program. With a valid oncologist’s prescription, diagnostic reports (including receptor/mutation status), and a government-issued patient ID, Indian Pharma Network facilitates compliant import in the patient’s name.

What is the price of Datroway in India?

Datroway is not sold on the open market in India, so the cost depends on sourcing, the number of vials required, logistics, and applicable duties at the time of import. A transparent, patient-specific quote is provided once the prescription is verified.

What is Datroway used for?

It treats certain HR-positive, HER2-negative, and triple-negative metastatic breast cancers, and EGFR-mutated non-small cell lung cancer after prior therapy.

Who is a reliable Datroway supplier in India?

Indian Pharma Network (IPN) is a trusted Datroway supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.

Who manufactures Datroway?

Datroway is developed and commercialised jointly by Daiichi Sankyo and AstraZeneca; it was discovered by Daiichi Sankyo.

What is the dosage form and strength of Datroway?

Datroway is supplied as a lyophilised powder in a single-dose vial, reconstituted and diluted for IV infusion. The recommended dose is 6 mg/kg every 3 weeks.

Who is an authorized Datroway importer in India?

Indian Pharma Network (IPN) acts as a Datroway importer in India. We help with Named Patient Import processes, regulatory documentation, and compliant procurement from leading international manufacturers for patients who need this therapy.

How is Datroway stored and delivered?

Datroway vials are stored refrigerated at 2 °C to 8 °C in the original carton, protected from light and not frozen, and shipped under validated cold-chain conditions to the patient or treating hospital.

Request Datroway price & availability:
Speak with our patient support team for Datroway price, quote, and guidance on the Named Patient import process. We respond within 24 hours on business days.

• Call: +91-96548 60915
• WhatsApp: +91-98104 69557
• Toll-free: 1800-1200-365
• Email: info@indianpharmanetwork.in

Because Datroway is not sold on the open market in India, there is no fixed MRP. The Datroway cost in India depends on a few factors at the time of import:

• The number of vials required per cycle, which is based on the patient’s body weight and the every-3-week dosing schedule (6 mg/kg per cycle).
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
  Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Datroway cost, logistics, and delivery timeline once a valid prescription is shared. Request your Datroway quote →

Datroway is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.

• Datroway (datopotamab deruxtecan-dlnk) US Prescribing Information, Daiichi Sankyo / AstraZeneca.
• US Food & Drug Administration — Datroway approval history (HR+/HER2- breast cancer 17 January 2025; EGFR-mutated NSCLC accelerated approval; metastatic TNBC 22 May 2026).

• European Medicines Agency (EMA) — Datroway product information.
• Breast Cancer Research Foundation (BCRF)

Content reviewed by the Indian Pharma Network clinical content team. Indications, dosing, and safety information are summarised from the manufacturer’s prescribing information.